FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381619805> ?p ?o ?g. }

• W4381619805 abstract "Abstract Study question Are intravenous immunoglobulins (IVIG) effective for the selected patients who experienced unexplained recurrent miscarriages (RM) that occurred at the same gestational weeks every time? Summary answer IVIG before and after the gestational week-limit (GWL), where miscarriage occurred at the same gestational weeks every time,may improve pregnancy outcomes in RM patients. What is known already Treatment for patients with unexplained RM are challenging. Since the efficacy of immunotherapy with paternal mononuclear cells has been denied in 1999, some treatment options (e.g., intralipid, G-CSF) have been published with conflicting results. In terms of IVIG, the same story has been described. Because previous studies for IVIG treatment included very heterogeneous group of patients, different dose, different intervals of IVIG, and different starting time of infusions. Recently, a double-blind, randomized, placebo-controlled study for unexplained RM women has been published in 2022, which revealed that IVIG (0.4g/kg) for five consecutive days at 4-5 weeks of gestation improved pregnancy outcomes. Study design, size, duration We performed a retrospective study between September 2013 and May 2021 in two fertility centers. We included 106 patients in the study who experienced 2 or more miscarriages between 5 and 21 weeks of gestation that occurred at the same gestational weeks every time, who had all negative results for our routine RM work up and still unsuccessful result after treating these conditions, and whose products of conceptus (POC) revealed at least one normal karyotype. Participants/materials, setting, methods IVIG (Venoglobulin IH 5%, Japan Blood Products Organization, 0.4g/kg) was injected twice before and after 1 week of GWL. If the GWL was 8 weeks of gestation, IVIG should be injected 7 and 9 weeks. We defined successful IVIG treatment as live birth. When the pregnancy ended in miscarriage, POC was performed as much as possible. All participants provided written informed consent, and Institutional Review Board approval was obtained. Main results and the role of chance Of 106 patients, average age was 37.5 years (28-47 years) and the mean number of previous miscarriages was 3.1. Total 128 cycles of IVIG attempt resulted in 90 (70.3%) successful pregnancies, 36 miscarriages and 2 biochemical pregnancies. After excluding abnormal karyotype of POC (N = 7), 68.6% (83/121) was successful. Per patients, 81.1% (86/106) had at least one live birth. Of 32 patients who experienced miscarriages at the first IVIG attempt, 16 patients got pregnant. Following second IVIG attempt resulted in 12 live births (75.0%). The average weight of live birth babies was 3038g and the birth week was 38.8 weeks of gestation (34-41 wk) for singleton pregnancy (N = 83), whereas 2529g with 35.9 weeks of gestation (33-37 wk) for twin pregnancy (N = 7). Four (4/83, 4.8%) and five (5/7, 71.4%) preterm deliveries were observed for singleton and twin pregnancy, respectively. One baby showed pulmonary hemorrhage resulting in hospitalization in the Neonatal Intensive Care Unit, other live birth babies were without any abnormal findings. Hypertensive disorders of pregnancy were noted in two women resulting in cesarian section delivery. Limitations, reasons for caution This study was retrospective study without any control group and was conducted at only two fertility centers. In future clinical research, it is necessary to conduct randomized controlled trials using placebo group to demonstrate the effectiveness of IVIG before and after the GWL using euploid blastocysts. Wider implications of the findings IVIG before and after the GWL adjusted for each patient may improve pregnancy outcomes in RM patients. Although IVIG is expensive, the current method requires only two IVIG injections, that may be acceptable for much more patients who want to avoid miscarriages and who didn’t use IVIG for economic reasons. Trial registration number not applicable" @default.
• W4381619805 created "2023-06-23" @default.
• W4381619805 creator A5003297637 @default.
• W4381619805 creator A5014067297 @default.
• W4381619805 creator A5023027925 @default.
• W4381619805 creator A5024002509 @default.
• W4381619805 creator A5036841612 @default.
• W4381619805 creator A5036877791 @default.
• W4381619805 creator A5086921954 @default.
• W4381619805 creator A5090336346 @default.
• W4381619805 creator A5091251773 @default.
• W4381619805 creator A5092234748 @default.
• W4381619805 creator A5092234749 @default.
• W4381619805 date "2023-06-01" @default.
• W4381619805 modified "2023-09-23" @default.
• W4381619805 title "P-494 Relevance of intravenous immunoglobulins in patients with unexplained recurrent miscarriages that occurred at the same gestational weeks every time" @default.
• W4381619805 doi "https://doi.org/10.1093/humrep/dead093.837" @default.
• W4381619805 hasPublicationYear "2023" @default.
• W4381619805 type Work @default.
• W4381619805 citedByCount "0" @default.
• W4381619805 crossrefType "journal-article" @default.
• W4381619805 hasAuthorship W4381619805A5003297637 @default.
• W4381619805 hasAuthorship W4381619805A5014067297 @default.
• W4381619805 hasAuthorship W4381619805A5023027925 @default.
• W4381619805 hasAuthorship W4381619805A5024002509 @default.
• W4381619805 hasAuthorship W4381619805A5036841612 @default.
• W4381619805 hasAuthorship W4381619805A5036877791 @default.
• W4381619805 hasAuthorship W4381619805A5086921954 @default.
• W4381619805 hasAuthorship W4381619805A5090336346 @default.
• W4381619805 hasAuthorship W4381619805A5091251773 @default.
• W4381619805 hasAuthorship W4381619805A5092234748 @default.
• W4381619805 hasAuthorship W4381619805A5092234749 @default.
• W4381619805 hasBestOaLocation W43816198051 @default.
• W4381619805 hasConcept C131872663 @default.
• W4381619805 hasConcept C142724271 @default.
• W4381619805 hasConcept C187212893 @default.
• W4381619805 hasConcept C204787440 @default.
• W4381619805 hasConcept C27081682 @default.
• W4381619805 hasConcept C2778279030 @default.
• W4381619805 hasConcept C2778376644 @default.
• W4381619805 hasConcept C2779234561 @default.
• W4381619805 hasConcept C2779245376 @default.
• W4381619805 hasConcept C2780625311 @default.
• W4381619805 hasConcept C46973012 @default.
• W4381619805 hasConcept C54355233 @default.
• W4381619805 hasConcept C71924100 @default.
• W4381619805 hasConcept C86803240 @default.
• W4381619805 hasConceptScore W4381619805C131872663 @default.
• W4381619805 hasConceptScore W4381619805C142724271 @default.
• W4381619805 hasConceptScore W4381619805C187212893 @default.
• W4381619805 hasConceptScore W4381619805C204787440 @default.
• W4381619805 hasConceptScore W4381619805C27081682 @default.
• W4381619805 hasConceptScore W4381619805C2778279030 @default.
• W4381619805 hasConceptScore W4381619805C2778376644 @default.
• W4381619805 hasConceptScore W4381619805C2779234561 @default.
• W4381619805 hasConceptScore W4381619805C2779245376 @default.
• W4381619805 hasConceptScore W4381619805C2780625311 @default.
• W4381619805 hasConceptScore W4381619805C46973012 @default.
• W4381619805 hasConceptScore W4381619805C54355233 @default.
• W4381619805 hasConceptScore W4381619805C71924100 @default.
• W4381619805 hasConceptScore W4381619805C86803240 @default.
• W4381619805 hasIssue "Supplement_1" @default.
• W4381619805 hasLocation W43816198051 @default.
• W4381619805 hasOpenAccess W4381619805 @default.
• W4381619805 hasPrimaryLocation W43816198051 @default.
• W4381619805 hasRelatedWork W1963624889 @default.
• W4381619805 hasRelatedWork W2023381783 @default.
• W4381619805 hasRelatedWork W2148025649 @default.
• W4381619805 hasRelatedWork W2160348035 @default.
• W4381619805 hasRelatedWork W2325097716 @default.
• W4381619805 hasRelatedWork W2333891256 @default.
• W4381619805 hasRelatedWork W2594069839 @default.
• W4381619805 hasRelatedWork W3163987424 @default.
• W4381619805 hasRelatedWork W4236177145 @default.
• W4381619805 hasRelatedWork W4319655794 @default.
• W4381619805 hasVolume "38" @default.
• W4381619805 isParatext "false" @default.
• W4381619805 isRetracted "false" @default.
• W4381619805 workType "article" @default.